AzTrials
AzTrials

EndotoxemiaNCT05752968

Elevated Levels of Antibodies to Endotoxin Core in Hemodialysis Patients With Peripheral Artery Disease

An observational study of Endotoxemia and Peripheral Arterial Disease, run by Tungs' Taichung Metroharbour Hospital at 1 site in Taiwan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background Peripheral arterial disease (PAD) and its relevant complications are more common in hemodialysis (HD) patients. The potential association regarding chronic kidney disease dysbiosis, inflammation and metabolic endotoxinemia in HD patients is unknown. Read more about this study

Who is it for?
Ages 20 years and older
Conditions the study is for
Endotoxemia, Peripheral Arterial Disease
How many people
155 participants
Where
1 siteTaiwan
Study dates
3 May 2023to 31 Dec 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: patients have to be at least 20-years-old and hemodialysis (HD) for at least 1 months.

Who may be able to join

  • A cohort of aged 20 or over, who receive hemodialysis with ultrapure dialysate three times weekly for at least 1 month.

Who cannot join

  • We will exclude patients dialyzed with a catheter; who had an acute infection requiring hospitalization; and who had underlying malignancy or autoimmune diseases. In addition, patients who refuse to participate will be excluded.

Trial locations and contacts

1 site in 1 country.

Taiwan1 site
  • Tungs' Taichung MetroHarbour Hospital

    Taichung

Other trials in Taiwan

About this study

Background

Peripheral arterial disease (PAD) and its relevant complications are more common in hemodialysis (HD) patients. The potential association regarding chronic kidney disease dysbiosis, inflammation and metabolic endotoxinemia in HD patients is unknown. A cross-sectional study will be carried out the evaluate the possible association endotoxin core antibody with asymptomatic PAD in a cohort of HD patients.

Read more

Methods

This cohort study enrolled 500 HD patients treated at a single center in Taichung city. Fasting blood samples will be collected to determine biochemical data Endotoxin core antibody levels and other related biomarkers. By the automatic oscillometric method, the ankle-brachial index (ABI) was measured. Low ABI was defined as any value < 0.9.

Read the detailed description

Study Design and Patients This is a cross-sectional study involving hemodialysis patients from the hemodialysis unit of Tungs' Taichung MetroHarbor Hospital, Taiwan. A total of 500 patients over 20 years of age who receive hemodialysis with ultrapure dialysate three times weekly for at least 1 month are eligible for enrollment. We will exclude patients dialyzed with a catheter; who had an acute infection requiring hospitalization; and who had underlying malignancy or autoimmune diseases. In addition, patients who refuse to participate will be excluded. Information on participant demographics and comorbidities will be obtained from interviews and medical record reviews at the time of enrollment. Diabetes mellitus is defined by self-reported history or use of antidiabetic medications. Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic ≥90 mmHg, or use of antihypertensive agents. Pre-exisiting CVD is defined as coronary artery disease, as documented by coronary angiography or a history of myocardial infarction, class III or IV congestive heart failure, or stroke. This study will comply with the Declaration of Helsinki and will apply for approval from the Institutional Review Board of Tungs' Taichung MetroHarbor Hospital. All participants will give their written informed consent.

Laboratory Measurements Predialysis blood samples are obtained on a mid-week day. Within 30 min after sampling, the remaining blood will be centrifuged at 3,000 g for 10 min, immediately aliquoted and frozen at-70 °C until further analysis. The total serum cholesterol is measured through the reaction of cholesterol esterase/cholesterol oxidase/ peroxidase, using Hitachi 747 (Hitachi, Bohemia, NY, USA). HDL cholesterol is quantified after precipitation with polyethylene glycol at room temperature. Serum glucose concentrations are measured by the glucose oxidase method. Low-density lipoprotein cholesterol is calculated using the Friedewald formula. Total serum triglycerides are measured through the reaction of glycerol/ phosphate/oxidase and peroxidase. The serum levels of high-sensitivity C-reactive protein (hsCRP) are measured using a Behring Nephelometer II (Dade Behring, Tokyo, Japan). Serum levels of IL-6 and sCD14 are measured by a commercially available enzyme-linked immunosorbent assay (Quantikine HS Immunoassay kit, R\&D System, Minneapolis, MN, USA). The LBP will be determined from serum samples and controls using standardized enzyme-linked immunosorbent assay methods (HK315-02, HyCult Biotech Inc., Uden, The Netherlands), and serum from 20 normal control subjects are used for interassay variation. Serum endotoxin core antibody will be tested using a commercially available EndoCab IgG ELISA assay (Hycult Biotech Inc., The Netherlands). In addition, serum LCN-2 (Lipocalin-2) and YKL-40 concentrations will be determined using enzyme linked immunosorbent assays

Endotoxin Measurement Endotoxin levels are measured using a Charles River Laboratories (CRL) Kinetic Chromogenic assay, Endochrome-K. A more detailed description of the methodology used has been described elsewhere [37]. Samples are thawed and diluted to 1 : 20 with a bio-dispersing agent (CRL, BD100) and heat to 75°C for 15 minutes. A standard curve (0.005 EU/mL and 5 EU/mL) is prepared using control standard endotoxin supplied by CRL. If endotoxin is detected, the samples are then reconstituted with an endotoxin-specific buffer (Charles River Endosafe BG-120) to avoid any β-glucan-related false positive reaction. A positive product control is included for each sample to eliminate the possibility of enhancement or inhibition of endotoxin measurement. The absorbance at 405 nm is measured at 30 second intervals for a total of 3600 seconds using a Biotek ELx808 plate reader. The assay reactions are held at 37°C throughout the assay period. Charles River Endosafe, EndoScan V software is used to generate a standard curve and analyze data using an onset time of 0.1 absorbance unit.

Keywords
Peripheral Arterial Disease, Endotoxin core antibody
Medical subject headings
Endotoxemia, Peripheral Arterial Disease

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Analysis of biomarkers of endotoxin core antibody (EndoCab) levels

    Plasma level of endotoxin core antibody (EndoCab) is a biomarkers for the risk of developing and presence of PAD

    Measured: 1 years

Secondary outcomes (5)
  1. Ankle Brachial Index Measurements

    Diagnostic criterion for asymptomatic PAD

    Measured: 1 years

  2. Analysis of biomarkers of IL-6

    The IL-6 was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods

    Measured: 1 years

  3. Analysis of biomarkers of sCD14

    The sCD14 was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods assay (ELISA) methods

    Measured: 1 years

  4. Analysis of biomarkers of LCN-2 (Lipocalin-2)

    The LCN-2 (Lipocalin-2) was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods

    Measured: 1 years

  5. Analysis of biomarkers of YKL-40

    The YKL-40 was determined from plasma samples using standardized enzymelinked immunosorbent assay (ELISA) methods

    Measured: 1 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Mar 2023
  2. Study start3 May 2023
  3. Primary completion31 Dec 2023
  4. Study completion31 Dec 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
155 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05752968
Sponsor's protocol ID
111064
Status last verified
Feb 2024
First submitted
21 Feb 2023
Last updated
1 Mar 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Endotoxemia and Peripheral Arterial Disease, run by Tungs' Taichung Metroharbour Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Analysis of biomarkers of endotoxin core antibody (EndoCab) levels (time frame: 1 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Mar 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in